Trial Profile
The effect of peroxisome proliferator activator receptor gamma agonist pre-treatment on pegylated interferon-alpha2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 25 Aug 2011
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms HEPAR
- 25 Aug 2011 New trial record